))
Episode 58: Samarendra Mohanty - President & CSO, Nanoscope Therapeutics
Manage episode 408954867 series 3526490
Innehåll tillhandahållet av Vial. Allt poddinnehåll inklusive avsnitt, grafik och podcastbeskrivningar laddas upp och tillhandahålls direkt av Vial eller deras podcastplattformspartner. Om du tror att någon använder ditt upphovsrättsskyddade verk utan din tillåtelse kan du följa processen som beskrivs här https://sv.player.fm/legal.
Dr. Samar Mohanty, president and CSO of Nanoscope Therapeutics joins us to shed light on the revolutionary gene therapy that's giving hope to individuals with retinal degenerative diseases by pioneering a treatment that can re-sensitize the retina to detect low light levels. We open the curtains on their groundbreaking multi-characteristic opsins (MCOs), which have the potential to address all forms of retinal degeneration and restore vision in millions of visually impaired individuals.
First In Human is a biotech-focused podcast that interviews industry leaders and investors to learn about their journey to in-human clinical trials. Presented by Vial, a tech-enabled CRO, hosted by Simon Burns, CEO & Co-Founder. Episodes launch weekly on Tuesdays. To view the full transcript of this episode, click here.
Interested in being featured as a guest on First In Human? Please reach out to owen@vial.com.
🎧 Stay in the Loop!
For the latest news and updates, visit our website: https://vial.com
Follow us on social media for real-time insights:
Twitter: https://twitter.com/VialTrials
LinkedIn: https://www.linkedin.com/company/vialtrials
Kapitel
1. Episode 58: Samarendra Mohanty - President & CSO, Nanoscope Therapeutics (00:00:00)
2. Revolutionary Gene Therapy for Vision (00:00:06)
3. The Future of Retinal Gene Therapy (00:15:32)
62 episoder
Dela
